Opportunity Information: Apply for PAR 16 059
Apply for PAR 16 059
- The HHS-NIH11 in the education, health sector is offering a public funding opportunity titled "Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.393, 93.394, 93.395, 93.396,.
- This funding opportunity was created on Dec 11, 2015 and posted on Dec 11, 2015.
- Applicants must submit their applications by May 07, 2017. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $450,000.00 in funding.
- Eligible applicants include: State governments, Public and State controlled institutions of higher education, Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For profit organizations other than small businesses, Small businesses, Others (see text field entitled Additional Information on Eligibility for clarification).
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01) funding opportunity (PAR-16-059) is an NIH research grant announcement intended to support projects that make mammalian cancer and tumor models more useful for translational research. In practical terms, it targets work that expands, improves, or significantly upgrades the models researchers rely on to connect basic discoveries to real-world clinical applications, such as prevention strategies, diagnostics, and therapies. The emphasis is on increasing the real-life relevance of these models to human cancer biology and treatment questions, so that findings generated in the lab have a clearer path toward benefiting patients.
This announcement replaces an earlier program (PAR-14-241) that focused specifically on mouse models. The key change is that the scope is broadened beyond mice to include any mammalian model system used to study cancer and tumors. That could include, for example, rats, companion animals, or other mammalian systems when scientifically justified. While the new FOA keeps the original intent of improving translational value, it explicitly invites a wider range of mammalian modeling approaches rather than limiting applicants to mouse-only solutions.
The award mechanism is an R01, meaning it is designed for hypothesis-driven or problem-focused research projects that can generate robust, publishable outcomes and usable resources, methods, or model improvements for the cancer research community. The stated purpose is not simply to run experiments within existing models, but to change what those models can do: increasing fidelity to human disease, enabling more predictive preclinical testing, improving how tumors arise and evolve in the model, or making the model more suitable for evaluating therapeutic response, resistance, metastasis, tumor microenvironment interactions, or other clinically relevant features. The overall theme is utility for translational research, which typically means better alignment with patient biology and greater confidence that interventions tested in the model will behave similarly in humans.
Eligible applicants are broad and include state governments; public and state-controlled institutions of higher education; private institutions of higher education; nonprofit organizations (both with and without 501(c)(3) status, excluding universities where specified); for-profit organizations other than small businesses; small businesses; and additional eligible entities as clarified in the full announcement. This wide eligibility reflects NIH’s interest in drawing proposals from academic labs, medical centers, research institutes, and industry groups that have the specialized expertise and infrastructure to build, refine, validate, and disseminate improved mammalian cancer models.
The sponsoring agency is the U.S. Department of Health and Human Services, National Institutes of Health (HHS-NIH11). The opportunity falls within the broader Education and Health activity category and lists CFDA numbers 93.393, 93.394, 93.395, and 93.396, indicating alignment with NIH cancer-related program areas. The posting and creation dates were December 11, 2015, and the application due date listed is May 7, 2017. The listed award ceiling is $450,000. The expected number of awards is not specified in the provided data, which usually means applicants should rely on the FOA text and NIH institute funding conditions for more precise expectations.
In summary, PAR-16-059 is essentially an NIH invitation to develop better mammalian cancer and tumor models that improve the credibility and applicability of preclinical cancer research for human translation. The defining feature of this updated FOA is the expansion from mouse-only to any mammalian system, as long as the proposed work meaningfully enhances translational relevance and strengthens the ability of researchers to move from mechanistic insights to clinically actionable outcomes.
Frequently Asked Questions (FAQs)
What is PAR-16-059?
PAR-16-059 is an NIH Funding Opportunity Announcement (FOA) titled "Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01)." It supports research projects that expand, improve, or substantially upgrade mammalian cancer and tumor models so they are more useful for translational research.
What is the main goal of this funding opportunity?
The main goal is to make mammalian cancer and tumor models more relevant to real-world human cancer biology and clinical questions. The focus is on improving the models themselves so that lab findings have a clearer path to prevention strategies, diagnostics, and therapies that can benefit patients.
What types of projects does this FOA aim to support?
This FOA is aimed at projects that enhance the usefulness of mammalian models for translational cancer research. Examples of model-focused improvements described include increasing fidelity to human disease, enabling more predictive preclinical testing, improving how tumors arise and evolve in the model, and making models better suited for studying therapeutic response, resistance, metastasis, and tumor microenvironment interactions.
Is this FOA limited to mouse models?
No. PAR-16-059 broadened the scope beyond mouse-only approaches. While an earlier program (PAR-14-241) focused specifically on mouse models, this announcement explicitly welcomes any mammalian model system used to study cancer and tumors, as long as the choice is scientifically justified.
What mammalian model systems could be included under this FOA?
The information provided indicates that the scope can include mice as well as other mammalian systems such as rats, companion animals, or other mammalian model systems, when scientifically justified for the cancer or tumor research question.
What does "translational research" mean in the context of this announcement?
In this FOA, translational research refers to work that helps connect basic research discoveries to clinical applications, including prevention approaches, diagnostics, and therapies. The emphasis is on aligning model behavior more closely with patient biology to improve confidence that results will translate to humans.
Does the FOA fund studies that only use existing models as-is?
The stated purpose is not simply to run experiments within existing models. The emphasis is on changing what the models can do by meaningfully improving, expanding, or upgrading them for greater translational value.
What grant mechanism is used for this opportunity?
The award mechanism is an NIH R01 research project grant, which is typically used for hypothesis-driven or problem-focused research projects that can produce robust, publishable outcomes and usable resources, methods, or model improvements for the broader research community.
Who is the sponsoring agency?
The sponsoring agency is the U.S. Department of Health and Human Services, National Institutes of Health (HHS-NIH11).
What activity category is this opportunity listed under?
It is listed within the Education and Health activity category.
Which CFDA numbers are associated with this opportunity?
The opportunity lists CFDA numbers 93.393, 93.394, 93.395, and 93.396, indicating alignment with NIH cancer-related program areas.
Who is eligible to apply?
Eligibility is broad and includes state governments; public and state-controlled institutions of higher education; private institutions of higher education; nonprofit organizations (with and without 501(c)(3) status, excluding universities where specified); for-profit organizations other than small businesses; small businesses; and additional eligible entities as clarified in the full announcement.
Are industry and small businesses eligible?
Yes. The provided eligibility list includes for-profit organizations other than small businesses, as well as small businesses.
What kinds of organizations is NIH trying to reach with this broad eligibility?
The broad eligibility reflects NIH interest in proposals from academic labs, medical centers, research institutes, and industry groups that have the expertise and infrastructure to build, refine, validate, and disseminate improved mammalian cancer models.
What is the application due date shown in the provided information?
The application due date listed is May 7, 2017.
When was this opportunity posted and created?
The posting and creation dates shown are December 11, 2015.
What is the award ceiling listed for this opportunity?
The listed award ceiling is $450,000.
How many awards are expected?
The expected number of awards is not specified in the provided information. In cases like this, applicants typically need to consult the FOA text and NIH institute funding conditions for more detail.
How is PAR-16-059 different from PAR-14-241?
PAR-16-059 replaces PAR-14-241. The earlier program focused specifically on mouse models, while PAR-16-059 expands the scope to include any mammalian model system used to study cancer and tumors, provided the model choice is scientifically justified and improves translational relevance.
What kinds of cancer research questions are highlighted as clinically relevant in the provided description?
The description highlights clinically relevant areas such as therapeutic response, resistance, metastasis, tumor evolution, and tumor microenvironment interactions, along with improving the overall fidelity of models to human disease.
What is the core theme that applications should align with?
The core theme is improving the utility of mammalian cancer and tumor models for translational research by increasing real-life relevance to human cancer biology and treatment questions.
Browse more opportunities from the same category: Education, Health
Next opportunity: Oral Health Service Expansion
Previous opportunity: Increase Access to Care for Black Men Who Have Sex with Men
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 16 059
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 16 059) also looked into and applied for these:
| Funding Opportunity |
|---|
| Applying Metabolomics to Drive Biomarker Discovery in Symptom Science (R01) Apply for PA 16 030 Funding Number: PA 16 030 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R21) Apply for RFA CA 16 001 Funding Number: RFA CA 16 001 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $200,000 |
| Applying Metabolomics to Drive Biomarker Discovery in Symptom Science (R21) Apply for PA 16 029 Funding Number: PA 16 029 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $200,000 |
| Effects of Drugs of Abuse on Latent HIV Reservoirs in the CNS (R01) Apply for RFA DA 16 014 Funding Number: RFA DA 16 014 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| NCI Research Specialist Award (R50) Apply for PAR 16 025 Funding Number: PAR 16 025 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Drug Discovery For Nervous System Disorders (R01) Apply for PAR 16 041 Funding Number: PAR 16 041 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| HIV/AIDS High Priority Drug Abuse Research (R01) Apply for PAS 16 018 Funding Number: PAS 16 018 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Exploring Epigenomic or Non-Coding RNA Regulation in HIV/AIDS and Substance Abuse (R01) Apply for RFA DA 16 012 Funding Number: RFA DA 16 012 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Genomic Data Analysis Network: Visualization Genomic Data Center (U24) Apply for RFA CA 15 019 Funding Number: RFA CA 15 019 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $660,000 |
| The NCI Predoctoral to Postdoctoral Fellow Transition Award (F99/K00) Apply for RFA CA 16 005 Funding Number: RFA CA 16 005 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Behavioral and Integrative Treatment Development Program (R03) Apply for PA 16 074 Funding Number: PA 16 074 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $50,000 |
| Clinical Development of Minimally-Invasive Bioassays to Support Outpatient Clinical Trials of Therapeutics for Substance Use Disorders (R21) Apply for PA 16 075 Funding Number: PA 16 075 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Behavioral and Integrative Treatment Development Program (R34) Apply for PA 16 073 Funding Number: PA 16 073 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $225,000 |
| Clinical Development of Minimally-Invasive Bioassays to Support Outpatient Clinical Trials of Therapeutics for Substance Use Disorders (R01) Apply for PA 16 076 Funding Number: PA 16 076 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $500,000 |
| Behavioral Science Track Award for Rapid Transition (B/Start)(R03) Apply for PAR 16 071 Funding Number: PAR 16 071 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $75,000 |
| Behavioral and Integrative Treatment Development Program (R01) Apply for PA 16 072 Funding Number: PA 16 072 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Feasibility Studies to Build Collaborative Partnerships in Cancer Research (P20) Apply for PAR 16 084 Funding Number: PAR 16 084 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $275,000 |
| Supplements to Promote Clinical Research Studies on Pediatric Burkitt Lymphoma in Low- and Middle-Income Countries (Admin Supp) Apply for PA 16 086 Funding Number: PA 16 086 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $100,000 |
| Imaging and Biomarkers for Early Cancer Detection (U01) Apply for PAR 16 089 Funding Number: PAR 16 089 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| SBIR Phase II Bridge Awards to Accelerate the Development of Cancer Therapeutics, Imaging Technologies, Interventional Devices, Diagnostics, and Prognostics toward Commercialization (R44) Apply for RFA CA 16 008 Funding Number: RFA CA 16 008 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $1,000,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 16 059", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.